Sequana Medical NV Overview
Pro stress-test →Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company commercializes the alfapump®, an implantable device approved by FDA, and Direct Sodium Removal (DSR) technology, targeting a significant unmet medical need in patients where standard diuretics are ineffective.
Strategic Profile
Pro stress-test →Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. The company announced strong commercial US progress with implants of the alfapump® System having been completed at five leading centers since launch in Q4 2025. The medtech company operates in a specialized niche with proprietary technology and clinical evidence supporting premium market positioning.
Competitive Landscape
Pro stress-test →Sequana Medical operates in the specialized medtech space for fluid management with limited direct competitors offering implantable solutions. Competitors in broader interventional cardiology and fluid management include companies like Endologix, though alfapump's proprietary design and clinical evidence provide differentiation. The company focuses on a specific high-acuity patient population underserved by pharmaceutical approaches.
Industry Context
Sequana Medical NV operates in Medical Devices - Cardiovascular and Hepatology Therapeutics.
Key facts
Founded: 2006 · Headquarters: Ghent, Belgium · Employees: 48 · Revenue: $0.106M · Market cap: $50.9M